Listing 1 - 10 of 27 | << page >> |
Sort by
|
Choose an application
La réponse du monde scientifique face aux résistances croissantes des bactéries aux antibiotiques est de repenser le développement des antiinfectieux en appliquant un concept qui marche déjà dans d'autres domaines thérapeutiques tels que l'oncologie et la neurologie : les multi-targets drugs. De par son mécanismed'action multiple, elles permettent d'avoir une meilleure efficacité tout en diminuant l'apparition de résistance aux médicaments. Leur application dans le domaine infectieux est encore à ses débuts : les molécules issues de la recherche telle que le SQ109 n'en sont encore qu'aux études cliniques de phase II, mais leur profil plus sûr et leur efficacité, notamment dans le traitement de la tuberculose, ont déjà été démontrés. Le SQ109 inhibe de nombreuses cibles comme (1) la MmpL3, responsable du transport de acides mycoliques dans la paroi ; (2) le MenA et le MenG, enzymes de la synthèse de la ménaquinone ; (3 la « proton motive force » ; (4) des protéines de la chaine de transport d'électrons. C'est cette diversité dans les cibles qui lui confère son activité non seulement contre Mycobacterium tuberculosis, mais aussi contre d'autres bactéries, des champignons et même des protozoaires. The answer of the scientific community to the increasing resistance of the bacteria to the antibiotics is to rethink the development of anti-infectious drugs a field-proven concept from other therapeutic domains such as oncology and neurology: the multi-target drugs. Thanks to its multi-action mechanisms, they give a better efficiency while decreasing the occurrence of drug resistance. Their application in the infectious field is still at its beginning: research molecules such as the SQ109 are still in the phase I clinical trials, but their safer profile and their efficiency, especially in the treatment of the tuberculosis were already proven. The SQ109 inhibits multiple targets such as (1) the MmpL3, responsible for the mycolic acids transportation inside the wall; (2) the MenA and the MenG, enzyms of the menaquinon synthesis; (3) the proton motive force ; (4) the proteins in the electron transport chain. This diversity of targets gives the SQ109 its activity against Mycobacterium tuberculosis as well as against other bacteria’s fungi, and even protozoan.
Choose an application
Written in clear, nontechnical language, this investigation of drug resistance provides readers with an overview of the scientific issues, the current scope of the problem nationally and globally, and the measures that can be taken to combat this public health crisis. Drug resistance-the reduction in the effectiveness of a particular medicine (particularly antimicrobials) in treating a disease or condition-is considered one of the most pressing issues in medicine today. This problem is likely to have profound impacts on society in the decades to come. This understandable, single-volume book explores the history of drug resistance, explains how drug resistance occurs, cites the most problematic examples, identifies the potential consequences, and describes how drug resistance can be prevented. It also pays attention to current issues and controversies surrounding this topic, such as the role of the industrialized food system in breeding antibiotic-resistant strains of E. coli. The coverage includes up-to-date information about specific diseases like tuberculosis, malaria, human immunodeficiency virus (HIV), and methicillin-resistant Staphylococcus aureus (MRSA), for which drug resistance is a particular issue. Readers will understand how human behavior, such as patient non-adherence to treatment and physician over-prescription of antibiotics, have served to foster drug resistance. A selection of primary documents sourced from organizations such as the World Health Organization, the U.S. Food and Drug Administration, and the Centers for Disease Control and Prevention will serve those interested in pursuing more detailed research on particular topics.
Choose an application
"As of 2017, the emergence and spread of antimicrobial resistance continues unabated around the world, leaving devastating health and economic outcomes in its wake. Those consequences will multiply if collaborative global action is not taken to address the spread of resistance. Major drivers of antimicrobial resistance in humans have been accelerated by inappropriate antimicrobial prescribing in health care practices; the inappropriate use of antimicrobials in livestock; and the promulgation of antibiotic resistance genes in the environment. To explore the issue of antimicrobial resistance, the Forum of Microbial Threats planned a public workshop. Participants explored issues of antimicrobial resistance through the lens of One Health, which is a collaborative approach of multiple disciplines - working locally, nationally, and globally - for strengthening systems to counter infectious diseases and related issues that threaten human, animal, and environmental health, with an end point of improving global health and achieving gains in development. They also discussed immediate and short-term actions and research needs that will have the greatest effect on reducing antimicrobial resistance, while taking into account the complexities of bridging different sectors and disciplines to address this global threat. This publication summarizes the presentations and discussions from the workshop"--
Drug resistance in microorganisms. --- Anti-infective agents.
Choose an application
La surconsommation d'antibiotiques responsable d'antibiorésistance est depuis quelques années au cœur de l'actualité des soins de Santé. En effet, de nombreux auteurs ainsi que de nombreuses campagnes de sensibilisation préconisent le juste usage des antibiotiques. L'émergence de bactéries résistantes est devenue une des plus grandes menaces pour la Société. De nombreuses questions se posent quant à une bonne utilisation de l'antibiothérapie. En effet, le Belgique est situé dans le top cinq des plus grands consommateurs d'antibiotiques comparativement aux Pays-Bas qui sont les derniers. Cette situation alarmante nécessite, dès lors, des mesures politiques en vue de réduire cette surconsommation et ainsi lutter contre l'antibiorésistance. Le pharmacien d'officine, spécialiste des médicaments, est le premier conseiller. Face à de l'antibiorésistance, à la surconsommation d'antibiotiques et à la diminution de l'efficacité de certains d'entre eux, ne doit-il pas avoir un rôle plus important dans la lutte contre l'usage abusif des antibiotiques ?De plus, les arrêts de traitement antibiotiques ou les erreurs de médications sont principalement dus à des manques ou à des défauts de formulation tant au niveau de la forme galénique, de la palatabilité que dans les utilisations pédiatriques. Pour faire face à ces problèmes, le pharmacien d'industrie ne devrait-il pas les affronter en vue d'un meilleur suivi de traitement ?Enfin, les antibiotiques encore efficaces à l'heure actuelle sont de plus en plus restreints. Ne serait-il pas grand temps d'investir dans la recherche de nouveaux antibactériens afin d'éviter une pénurie et de se retrouver à l'époque où les antibiotiques n'existaient pas ? Overuse of antibiotics, which cases antibiotic resistance, has been a key topic in the healthcare-related headlines. Many authors and awareness campaigns do indeed recommend using antibiotics cautiously. The emergence of antibiotic-resistant, bacteria became one of the biggest threats to society. Many questions arise as to the goof use of antibiotic therapy. Belgium is actually in the top five of the biggest consumes of antibiotics whereas Netherlands is in last position. Given this alarming situation, political measures are needed to reduce this overuse and to fight against antibiotic resistance. The first person to give advice is the pharmacist. Facing antibiotics resistance, antibiotics overuse and the decreasing effectiveness of some antibiotics, shouldn’t he play a bigger role in the fight against the misuse of antibiotics? Moreover, stoppages of antibiotic treatments and medication errors are mainly due to a lack or defect of formulation at the galenic or palatability levels or when use in pediatrics. Shouldn’t’ the industrial pharmacist face these problematics in order to cope with them and to reach a better follow-up of the treatment? Finally, efficient antibiotics are more and more rare. Isn’t it high time to invest in researches for new antibacterials and this way avoid a shortage and a step back to when antibiotics didn’t’ exist?
Compliance --- Pharmacists --- Child --- Drug Resistance, Bacterial
Choose an application
Choose an application
This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Cancer research --- Clinical sciences --- Medical profession --- Liver --- Drug resistance in cancer cells. --- Cancer --- Chemotherapy. --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells --- Oncology. --- Tumors
Choose an application
This book is a compilation of past and recent knowledge in the field of emerging drug resistance. The book covers major aspects of drug resistance in bacteria, fungi, malaria, and cancer. Human survival on earth is constantly threatened by disease and syndrome. From the early days, the aim of research in medicine was to find therapeutic agents that can improve the quality of human life. Although humans are dependent on natural compounds from early days their dependence of drugs increased excessively in last century. The advances in chemistry and biology have helped researchers to identify the drugs that have improved treatment of many diseases. The primary factor for treatment of these diseases is dependent on the efficacy of drugs available. The development of resistance to these drugs is one of the major hindrances. Although there are number of books available on this topic, “drug resistance” biology across kingdoms has never been discussed in a coherent way.
Medicine. --- Cancer research. --- Drug resistance. --- Cell biology. --- Bacteriology. --- Biomedicine. --- Drug Resistance. --- Cell Biology. --- Cancer Research. --- Drug resistance in microorganisms. --- Drug resistance in cancer cells. --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Antibiotic resistance in microorganisms --- Antibiotics resistance in microorganisms --- Bacterial resistance to antibiotics --- Drug resistance in micro-organisms --- Microbial drug resistance --- Resistance to drugs in microorganisms --- Cancer cells --- Microorganisms --- Effect of drugs on --- Drug interactions. --- Cytology. --- Oncology. --- Microbiology --- Tumors --- Cell biology --- Cellular biology --- Biology --- Cells --- Cytologists --- Interactions, Drug --- Drugs --- Side effects --- Cancer research --- Resistance to drugs --- Pharmacology
Choose an application
This is a comprehensive tool covering all manifestations of antimicrobial resistance, with viral, bacterial, parasitical and fungal resistance each given a dedicated section. The underlining molecular mechanisms, which depend not only on the microbe, but on the specific drug (target), are highly diverse, and are covered in great detail. This work also discusses and compares the biological, biochemical and structural aspects of resistance and its evolution.
Medicine. --- Drug resistance. --- Biomedicine. --- Drug Resistance. --- Resistance to drugs --- Clinical sciences --- Medical profession --- Drug interactions. --- Interactions, Drug --- Drugs --- Side effects --- Drug resistance in microorganisms --- Antibiotic resistance in microorganisms --- Antibiotics resistance in microorganisms --- Bacterial resistance to antibiotics --- Drug resistance in micro-organisms --- Microbial drug resistance --- Resistance to drugs in microorganisms --- Microorganisms --- Effect of drugs on
Choose an application
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. .
Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Cancer research --- Breast --- Drug resistance in cancer cells. --- Cancer --- Chemotherapy. --- Antitumor drug resistance --- Cancer drug resistance --- Drug resistance in cancer --- Drug resistance in tumor cells --- Cancer cells --- Oncology. --- Tumors
Choose an application
Antimicrobial Stewardship (AMS), Volume Two includes the experience of ESGAP workshops and courses on antibiotic stewardship since 2012. It combines clinical and laboratory information about AMS, with a focus on human medicine.The ESCMID study group on antibiotic policies (ESGAP) is one of the most productive groups in the field, organizing courses and workshops. This book is an ideal tool for the participants of these workshops.With short chapters (around 1500 words) written on different topics, the authors insisted on the following points: A hands on, practical approach, tips to increase success, a description of the most common mistakes, a global picture (out- and inpatient settings, all countries) and a short list of 10-20 landmark references.. Focuses on the most recent antimicrobial stewardship strategies. Provides a detailed description of laboratory support. Offers a balanced synthesis of basic and clinical sciences for each individual case, presenting clinical courses of the cases in parallel with the pathogenesis and detailed microbiological information for each infection. Describes the prevalence and incidence of the global issues and current therapeutic approaches. Presents the measures for infection control
Listing 1 - 10 of 27 | << page >> |
Sort by
|